CAS 242478-38-2 Solifenacin Succinate (HCID 216457)

名称と識別子

優先名称: Solifenacin Succinate
IUPAC: [(3R)-1-azabicyclo[2.2.2]octan-3-yl] (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate;butanedioic acid
現地名: ソリフェナシンこはく酸塩
英語名: Solifenacin succinate
分子式: C27H32N2O6
分子量: 480.56

名称と別名

Solifenacin succinate242478-38-2VesicareYM905YM 905KKA5DLD701YM-905YM67905YM-67905VESICARE LSsolifenacin succiatesolifenacine succinate

名称をさらに表示

ソリフェナシンこはく酸塩こはく酸ソリフェナシンコハク酸ソリフェナシン (JAN)(1S)-1-フェニル-1,2,3,4-テトラヒドロ-2-イソキノリンカルボン酸(3R)-キヌクリジン-3-イル・こはく酸(1S)-1,2,3,4-テトラヒドロ-1-フェニルイソキノリン-2-カルボン酸(3R)-1-アザビシクロ[2.2.2]オクタン-3α-イル・こはく酸(1S)-1-フェニル-1,2,3,4-テトラヒドロイソキノリン-2-カルボン酸(3R)-キヌクリジン-3-イル・こはく酸ソリフェナシンスクシナートベシケア(1S)-1-フェニル-1,2,3,4-テトラヒドロ-2-イソキノリンカルボン酸=(3R)-キヌクリジン-3-イル=コハク酸塩CS-353VesikurYM 67905Solfenacin42478-38-2IsoprenalinoeSulfateSolefinacin SuccinateSophenazine succinate

Succinate, SolifenacinRefChem:6251solifenacin succinate 5 mgsolifenacin succinate 10 mgSolifenacin Succinate Tablets905, YMquinuclidin-3'-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate monosuccinateSolifenacin succinate [USAN]

データベース識別子

CAS: 242478-38-2
PubChem CID: 216457
DTXSID: DTXSID30947075
ChEMBL: CHEMBL1200803
ChEBI: CHEBI:32151
UNII: KKA5DLD701
EC Number: 620-505-5

物性

構造計算による物性

極性表面積: 107 Å²
水素結合供与体数: 2
水素結合受容体数: 7
回転可能結合数: 6
重原子数: 35
形式電荷: 0
複雑度: 617

実験および物理化学的性質

Collision Cross Section201 Å² [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

物理化学的性質

融点: 145 ° · ~145°
貯蔵温度: 2 · under inert gas (nitrogen or Argon) at 2-8°C
溶解性: メタノール（わずかに、加熱、超音波処理）、水（わずかに、超音波処理）
外見: 個体
色: ホワイトからオフホワイト
水溶解度: 2 O: · H2O: 2mg/mL, clear
Merck: 14 · 14,8712
安定性: 吸湿性
InChIKey: RXZMMZZRUPYENV-ZFHAYXBFNA-N
SMILES: C(C(=O)O)CC(=O)O.C(N1CCC2=CC=CC=C2[C@@H]1C1C=CC=CC=1)(=O)O[C@H]1CN2CCC1CC2 |&1:18,27,r|
CAS データベース: 242478 · 242478-38-2(CAS DataBase Reference)

化学的性質

化学的特性White Solid

安全と法規制

GHS分類

GHS Classification · 5 件

Warning

H302 (92.8%): Harmful if swallowed [Warning Acute toxicity, oral]

P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 69 reports by companies from 12 notifications to the ECHA C&L Inventory.；Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website.

危険有害性情報

Hazard Classes and CategoriesAcute Tox. 4 (92.8%)

毒性情報

Drug Induced Liver Injury · 6 件

Drug Induced Liver Injury Rank (DILIrank 2.0)

Solifenacin succinate

vLess-DILI-concern

3

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation · 1 件

◉ Summary of Use during Lactation；Because there is no published experience with solifenacin during breastfeeding and it has a long half-life averaging 55 hours, an alternate drug may be preferred, especially while nursing a newborn or preterm infant. Long-term use of solifenacin might reduce milk production or milk letdown. During long-term use, observe the infant for signs of decreased milk production (e.g., insatiety, poor weight gain) and for anticholinergic symptoms (e.g., constipation, urinary retention, UTI, dry mouth).；◉ Effects in Breastfed Infants；Relevant published information was not found as of the revision date.；◉ Effects on Lactation and Breastmilk；Anticholinergics can inhibit lactation in animals, apparently by inhibiting growth hormone and oxytocin secretion. Anticholinergic drugs can also reduce serum prolactin in nonnursing women. The prolactin level in a mother with established lactation may not affect her ability to breastfeed.

安全データ

wgk: WGK 3
rtecs: NW7136000
hs_code: 29339900
Hazard Classifications: Repr. 2
ストレージクラス: 11 - Combustible Solids

化学と産業

薬理情報

FDA Pharmacological Classification · 6 件

SOLIFENACIN SUCCIATE

Cholinergic Muscarinic Antagonist [EPC]; Cholinergic Muscarinic Antagonists [MoA]

SOLIFENACIN SUCCINATE

Cholinergic Muscarinic Antagonist [EPC]; Cholinergic Muscarinic Antagonists [MoA]

SOLIFENACIN SUCCINATE TABLETS

Cholinergic Muscarinic Antagonists [MoA]; Cholinergic Muscarinic Antagonist [EPC]

MeSH Pharmacological Classification · 2 件

Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system.

Drugs used in the treatment of urological conditions and diseases such as URINARY INCONTINENCE and URINARY TRACT INFECTIONS.

応用分野 · 2 件

使用Solifenacin succinate is a urinary antispasmodic of the antimuscarinic class.

一般的な説明Solifenacin succinate (Vesicare),(+)-(1S, 3'R)-quinuclidin-3'-yl 1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate, is a competative antagonistfor M1, M2, and M3 receptor subtypes. One of the issues surroundingthe use of such antagonists is the selectivity for thebladder over other tissue such as the salivary glands. It isreported that the selectivity of solifenacin for bladder muscarinicreceptors over salivary receptors is superior to theeffects observed with oxybutynin.